Exchange: HKSE Sector: Biotechnology Industry: Biotechnology
13.21% HKD1.200
America/New_York / 3 mai 2024 @ 03:13
FUNDAMENTALS | |
---|---|
MarketCap: | 527.28 mill |
EPS: | -2.67 |
P/E: | -0.450 |
Earnings Date: | Mar 28, 2024 |
SharesOutstanding: | 439.40 mill |
Avg Daily Volume: | 8.88 mill |
RATING 2024-05-02 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.450 | sector: PE 9.44 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.450 | industry: PE 35.62 |
DISCOUNTED CASH FLOW VALUE |
---|
HKD0.505 (-57.94%) HKD-0.695 |
Date: 2024-05-03 |
Expected Trading Range (DAY) |
---|
HKD 1.132 - 1.268 ( +/- 5.67%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | HKD1.200 (13.21% ) |
Volume | 7.34 mill |
Avg. Vol. | 8.88 mill |
% of Avg. Vol | 82.65 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.